Quest Diagnostics Incorporated (NYSE:DGX - Free Report) - Equities research analysts at Zacks Research cut their Q1 2027 earnings estimates for shares of Quest Diagnostics in a note issued to investors on Thursday, November 12th. Zacks Research analyst Team now expects that the medical research company will earn $2.61 per share for the quarter, down from their previous forecast of $2.72. The consensus estimate for Quest Diagnostics' current full-year earnings is $11.29 per share. Zacks Research also issued estimates for Quest Diagnostics' Q3 2027 earnings at $3.08 EPS, FY2027 earnings at $11.69 EPS, Q1 2028 earnings at $2.97 EPS, Q2 2028 earnings at $3.24 EPS and FY2028 earnings at $12.77 EPS.
Quest Diagnostics (NYSE:DGX - Get Free Report) last released its quarterly earnings results on Thursday, October 22nd. The medical research company reported $3.00 earnings per share for the quarter, beating analysts' consensus estimates of $2.87 by $0.13. Quest Diagnostics had a net margin of 9.53% and a return on equity of 16.21%. The company had revenue of $3.10 billion for the quarter, compared to analyst estimates of $3.05 billion. During the same period last year, the firm earned $2.60 earnings per share. The firm's revenue was up 10.0% on a year-over-year basis.
Several other equities analysts have also issued reports on the company. JPMorgan Chase & Co. upped their target price on Quest Diagnostics from $220.00 to $250.00 and gave the company a "neutral" rating in a report on Tuesday, July 28th. UBS Group reiterated a "neutral" rating and set a $250.00 price target on shares of Quest Diagnostics in a report on Monday, October 19th. Truist Financial boosted their price objective on Quest Diagnostics from $250.00 to $260.00 and gave the stock a "hold" rating in a research report on Monday, September 21st. Weiss Ratings upgraded Quest Diagnostics from a "buy (a)" rating to a "buy (a+)" rating in a research note on Wednesday, October 21st. Finally, Argus set a $260.00 price objective on Quest Diagnostics in a research note on Wednesday, July 29th. One research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and five have assigned a Hold rating to the stock. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $248.70.
View Our Latest Stock Analysis on DGX
Quest Diagnostics Trading Down 0.1%
NYSE:DGX opened at $259.46 on Monday. Quest Diagnostics has a 52 week low of $171.18 and a 52 week high of $262.00. The firm has a 50-day moving average price of $241.23 and a two-hundred day moving average price of $215.58. The company has a debt-to-equity ratio of 0.70, a quick ratio of 1.58 and a current ratio of 1.70. The firm has a market cap of $28.55 billion, a price-to-earnings ratio of 25.84, a price-to-earnings-growth ratio of 2.32 and a beta of 0.54.
Institutional Investors Weigh In On Quest Diagnostics
Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Entropy Technologies LP lifted its holdings in Quest Diagnostics by 439.6% during the third quarter. Entropy Technologies LP now owns 31,185 shares of the medical research company's stock valued at $7,268,000 after purchasing an additional 25,406 shares during the last quarter. Jump Financial LLC boosted its position in Quest Diagnostics by 2,058.3% during the third quarter. Jump Financial LLC now owns 25,403 shares of the medical research company's stock worth $5,921,000 after purchasing an additional 24,226 shares during the period. Financial Advisors Network Inc. bought a new position in Quest Diagnostics during the third quarter worth about $202,000. EP Wealth Advisors LLC boosted its position in Quest Diagnostics by 19.1% during the third quarter. EP Wealth Advisors LLC now owns 4,165 shares of the medical research company's stock worth $971,000 after purchasing an additional 667 shares during the period. Finally, Empowered Funds LLC increased its stake in shares of Quest Diagnostics by 79.3% in the third quarter. Empowered Funds LLC now owns 19,050 shares of the medical research company's stock worth $4,440,000 after purchasing an additional 8,426 shares in the last quarter. 88.06% of the stock is currently owned by institutional investors.
Insiders Place Their Bets
In other Quest Diagnostics news, EVP Catherine Doherty sold 22,105 shares of the firm's stock in a transaction on Tuesday, November 3rd. The stock was sold at an average price of $248.02, for a total value of $5,482,482.10. Following the completion of the sale, the executive vice president directly owned 71,949 shares of the company's stock, valued at $17,844,790.98. This trade represents a 23.50% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Gary Pfeiffer sold 1,203 shares of the business's stock in a transaction on Monday, October 26th. The shares were sold at an average price of $243.00, for a total value of $292,329.00. Following the completion of the sale, the director owned 29,802 shares in the company, valued at approximately $7,241,886. The trade was a 3.88% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 67,702 shares of company stock valued at $16,730,269. Company insiders own 0.88% of the company's stock.
Quest Diagnostics Dividend Announcement
The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, January 27th. Shareholders of record on Tuesday, January 12th will be issued a dividend of $0.86 per share. This represents a $3.44 annualized dividend and a yield of 1.3%. The ex-dividend date of this dividend is Tuesday, January 12th. Quest Diagnostics's dividend payout ratio is 34.26%.
More Quest Diagnostics News
These are some of the DGX news items that stood out recently:
- Positive Sentiment: A Yahoo Finance article says DGX could be 31% undervalued following a push for the RESULTS Act, providing a potentially supportive policy and valuation angle. Quest Diagnostics stock could be undervalued following RESULTS Act push
- Positive Sentiment: Zacks Research raised several earnings forecasts, including its FY2026 EPS estimate to $11.28 from $11.15 and its Q2 2027 estimate to $3.09 from $2.99. The improved forecasts may support investor confidence, though the FY2026 estimate remains close to the $11.29 consensus.
- Positive Sentiment: Quest announced a quarterly dividend of $0.86 per share, equivalent to $3.44 annually and a stated yield of about 1.3%. The announcement coincided with DGX reaching a new one-year high. Quest Diagnostics hits a one-year high following dividend announcement
Quest Diagnostics Company Profile
(
Get Free Report)
Quest Diagnostics NYSE: DGX is a provider of diagnostic information services, conducting laboratory tests that help physicians and other health care professionals diagnose, monitor and manage medical conditions. Its services include routine blood and other clinical laboratory testing, anatomic pathology, and specialized molecular and genetic testing. The company serves patients, physicians, hospitals, health plans, employers and government organizations. In addition to testing performed through its laboratories and patient service centers, Quest offers services such as workplace drug testing and diagnostic support for clinical research.
Featured Articles

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Quest Diagnostics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Quest Diagnostics wasn't on the list.
While Quest Diagnostics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.